moa of glp 1 agonists Mechanisms action of GLP-1RA Non-insulin injectable antidiabetic drugs -
Description
Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications
Doses increase over time, sometimes up to 10 mg, 12.5 mg, or 15 mg weekly, to get strong results
Bottom Line GLP-1 agonists have a place in medicine as treatment for Type 2 diabetes and obesity, offering benefits in blood sugar control and weight loss
Ramos Belinchn et al
Once an effective dose is reached and HbA1c targets are met, the focus shifts to maintenance
These compounds share some mechanisms, but they diverge in ways that directly affect dosing, side effects, and outcomes
